RxDoctor Payments Data

Robert Otto

Psychiatric/Mental Health · Edwardsville, KSNPI 1033585609

Payments from drug & device makers

$2,619in general payments, 2019–2025

Across 150 payments — averaging $17.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$766
  • Teva Pharmaceuticals USA, Inc.$731
  • Alkermes, Inc.$349
  • E.r. Squibb & Sons, L.L.C.$235
  • Acadia Pharmaceuticals Inc$132
  • Otsuka America Pharmaceutical, Inc.$101
  • plus $305 from 6 others

What the payments were for

  • Food & beverage$2,45194%
  • Education$1686%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,619 in reported general payments places this provider in the 75th percentile of 404 psychiatric/mental health providers in Kansas.

See all psychiatric/mental health providers in Kansas

Medicare billing

Part B allowed, 2024
$209,738
Medicare patients
625
Services billed
2,616

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine203$1,350,183
Invega SustennaPaliperidone Palmitate101$376,742
IngrezzaValbenazine Tosylate35$232,891
AustedoDeutetrabenazine66$218,181
LybalviOlanzapine/Samidorphan Malate57$79,705
VraylarCariprazine Hcl71$54,032
Divalproex Sodium449$27,428
Clozapine585$22,577
NuedextaDextromethorphan Hbr/Quinidine33$20,809
RexultiBrexpiprazole22$19,452
Aripiprazole288$19,447
Haloperidol282$14,306
Haloperidol Decanoate154$11,337
Paliperidone ErPaliperidone46$9,231
Bupropion XlBupropion Hcl277$8,708

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo$731$1,568,364269 claims
Johnson & JohnsonInvega Sustenna$39$376,742101 claims
Neurocrine Biosciences, Inc.Ingrezza$766$232,89135 claims
Alkermes, Inc.Lybalvi$349$79,70557 claims
AbbVieVraylar$66$54,03271 claims
Otsuka America Pharmaceutical, Inc.Rexulti$101$19,45222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 404 psychiatric/mental health providers in Kansas.

Other psychiatric/mental health in Edwardsville

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →